SpringWorks Therapeutics (SWTX) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free SWTX Stock Alerts $44.84 +0.07 (+0.16%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 7:33 AM | marketbeat.comMassachusetts Financial Services Co. MA Buys 60,652 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Massachusetts Financial Services Co. MA raised its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 14.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 468,078 shares of the company's stock after buying an additional 60,652May 19 at 1:38 AM | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) versus SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head ComparisonMay 15, 2024 | americanbankingnews.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Buy" by AnalystsMay 15, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Rating of "Buy" from BrokeragesSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price amonMay 12, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Victory Capital Management Inc.Victory Capital Management Inc. grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 795.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 369,367 shares of the company's stock after acquiring an additional 328,127 shaMay 9, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for SpringWorks Therapeutics, Inc. Raised by HC Wainwright (NASDAQ:SWTX)May 8, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceMay 6, 2024 | markets.businessinsider.comStrong Buy Rating for Springworks Therapeutics Amidst Ogsiveo’s Market Success and Robust PipelineMay 6, 2024 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday.May 5, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Announces Earnings ResultsSpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) posted its earnings results on Thursday. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The firm had revenue of $21.00 million for the quarter, compared to analyst estimates of $12.07 million. During the same quarter last year, the firm posted ($1.18) earnings per share. The business's revenue was up 2000.0% compared to the same quarter last year.May 3, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationMay 2, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)Wedbush restated an "outperform" rating and set a $75.00 price objective (up from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday.May 2, 2024 | markets.businessinsider.comBuy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising PipelineMay 2, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeSpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume IncreaseMay 2, 2024 | investorplace.comSWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024May 2, 2024 | washingtonpost.comSpringWorks Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesMay 1, 2024 | msn.comSpringWorks Therapeutics Q1 2024 Earnings PreviewApril 25, 2024 | seekingalpha.comSpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer ClearApril 24, 2024 | globenewswire.comSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 20, 2024 | marketbeat.comMutual of America Capital Management LLC Invests $2.34 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Mutual of America Capital Management LLC purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 64,214 shares of the companApril 19, 2024 | seekingalpha.comSpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire WinnersApril 19, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 3%SpringWorks Therapeutics (NASDAQ:SWTX) Trading 3% HigherApril 18, 2024 | globenewswire.comSpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024April 15, 2024 | nasdaq.comSWTX Quantitative Stock AnalysisApril 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Has $1.49 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)DekaBank Deutsche Girozentrale grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 131.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the company'sApril 11, 2024 | marketbeat.comPeregrine Capital Management LLC Has $4.96 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Peregrine Capital Management LLC cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 14.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 136,009 shares of the company's sMarch 26, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Recommendation of "Buy" from AnalystsShares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) have earned an average rating of "Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target aMarch 17, 2024 | finance.yahoo.comSWTX Apr 2024 70.000 callMarch 16, 2024 | marketbeat.comWalleye Capital LLC Increases Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Walleye Capital LLC grew its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 196.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 144,307 shares of the company's stock after buying an additional 95,694 shares during the quarter. WalleyeMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 11, 2024 | marketbeat.comEquities Analysts Issue Forecasts for SpringWorks Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2024 EPS estimates for shares of SpringWorks Therapeutics in a research note issued to investors on Wednesday, March 6th. HC Wainwright analyst R. Burns now forecasts that the compaMarch 8, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Reaches New 52-Week High at $53.92SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 52-Week High at $53.92March 6, 2024 | finance.yahoo.comSWTX Apr 2024 60.000 putMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 65.000 callMarch 6, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Price Target Raised to $74.00HC Wainwright lifted their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a "buy" rating in a research note on Wednesday.March 4, 2024 | globenewswire.comSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNMarch 4, 2024 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stake Lessened by Deutsche Bank AGDeutsche Bank AG reduced its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 59.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,671 shares of the company's stockMarch 1, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Increases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Charles Schwab Investment Management Inc. increased its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 16.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 423,764 shares of the company's stock after purchasing an additional 59,138 shFebruary 29, 2024 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) PT Raised to $63.00 at BarclaysBarclays upped their target price on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an "overweight" rating in a research note on Thursday.February 29, 2024 | globenewswire.comSpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsFebruary 29, 2024 | marketbeat.comWedbush Analysts Increase Earnings Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Wedbush boosted their Q1 2024 earnings per share estimates for SpringWorks Therapeutics in a report released on Tuesday, February 27th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($1.2February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)February 28, 2024 | marketbeat.comFY2023 EPS Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Raised by AnalystSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Stock analysts at Wedbush raised their FY2023 EPS estimates for SpringWorks Therapeutics in a research note issued on Monday, February 26th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($5.02) per share forFebruary 28, 2024 | marketbeat.comProfund Advisors LLC Lowers Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Profund Advisors LLC trimmed its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 30.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,719 shares of the compaFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)February 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX) and ACADIA Pharmaceuticals (ACAD) Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. SWTX Media Mentions By Week SWTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SWTX News Sentiment▼0.840.42▲Average Medical News Sentiment SWTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SWTX Articles This Week▼43▲SWTX Articles Average Week Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Iovance Biotherapeutics News Today Denali Therapeutics News Today Immunocore News Today Twist Bioscience News Today Arcellx News Today Vericel News Today Recursion Pharmaceuticals News Today Apogee Therapeutics News Today Kymera Therapeutics News Today ADMA Biologics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SWTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
